A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.

Pfizer

Status: Completed

Conditions: Neoplasms

Treatments: Drug: SU011248

Study type: Interventional

Funder types: Industry

Identifiers

NCT00443534

A6181078

Details and patient eligibility

About

This protocol allows subjects who have participated in a previous SU011248 protocol the ability to continue to receive SU011248 after their study has ended.

Enrollment: 123 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participation in a previous SU011248 protocol and are judged by the investigator to have the potential to derive clinical benefit by remaining on SU011248 after the prior protocol ends.

Exclusion criteria

• Severe acute or chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the patient inappropriate for entry into this study.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

123 participants in 1 patient group

1

Experimental group

Treatment:

Drug: SU011248